Search - tctmd.com

Displaying 1 - 20 of 85

Sort: Relevancy | Date

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Caitlin E. Cox

November 18, 2024

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

Shelley Wood

November 18, 2024

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Yael L. Maxwell

November 16, 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

News Conference News AHA 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

L.A. McKeown

November 17, 2023

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Todd Neale

November 13, 2023

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

L.A. McKeown

November 11, 2022

Advertisement

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

What’s Going to Be Hot at AHA 2025?

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

What’s Going to Be Hot at AHA 2023

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content